At this time, I'd like to welcome everyone to the Biogen fourth-quarter and full-year 2024 earnings call and business update.

In a report released today, George Farmer from Scotiabank maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of ...

Piper Sandler analyst David Amsellem maintained a Hold rating on Biogen (BIIB – Research Report) today and set a price target of $138.00. The ...

Q4 2024 Earnings Call Transcript February 12, 2025 Operator: Good morning. My name is Jennifer and I will be your conference ...

The company posted fourth-quarter adjusted EPS of $3.44, up 17%, beating the consensus of $3.35. The company reported sales ...

Biogen Inc. (NASDAQ:BIIB – Get Free Report) traded down 6.8% during trading on Wednesday after Bank Of America (Bofa) lowered ...

Biogen (NASDAQ:BIIB) stock traded flat as the company reports better than expected Q4 2024 financials, but its 2025 outlook ...

Q4 2024 Earnings Conference Call February 12, 2025 8:30 AM ETCompany ParticipantsTim Power - Head of IRChris Viehbacher ...

We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts. In this article, we are going to ...

Biogen beat Q4 estimates with a 17% EPS rise and $2.46 billion in sales. The company expects revenue declines in 2025 as multiple sclerosis drug sales drop.

Biotech giant Biogen Inc (NASDAQ:BIIB) is scheduled to report fourth-quarter earnings on 12 February. The Wall Street ...

Biogen Inc. CEO Christopher Viehbacher gave investors an overview of what type of deals the company is looking for Wednesday ...